Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.

中文翻译：

---

AML 中的最小/可测量残留疾病：ELN MRD 工作组的共识文件

可测量残留病（MRD；以前称为微小残留病）是急性髓性白血病 (AML) 中独立的、诊断后的预后指标，与其他成熟的临床、细胞遗传学和分子诊断时评估的数据。MRD 可以使用各种多参数流式细胞术和分子方案进行评估，但迄今为止，这些方法尚未定性或定量标准化，使其在临床实践中的应用具有挑战性。这项工作的目的是确定在 AML 中测量和应用 MRD 的关键临床和科学问题，就这些问题达成共识，并为当前和未来在临床实践中使用 MRD 提供指南。这项工作历时 2 年，由欧洲白血病网的一个特别指定的 MRD 工作组在 4 次会议期间完成。该小组包括来自欧洲和美国 19 个机构的 24 名在 AML 血液病理学、分子诊断、临床试验和临床医学方面具有专业知识的教师。